losartan has been researched along with Dilatation, Pathologic in 21 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Dilatation, Pathologic: The condition of an anatomical structure's being dilated beyond normal dimensions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term outcome of Marfan syndrome patients randomly assigned to losartan or atenolol showed no differences in aortic dilation rate or presence of clinical events between treatment groups." | 9.27 | Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. ( Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G, 2018) |
| "In this multicentre, open-label, randomized controlled trial with blinded assessments, we compared losartan treatment with no additional treatment in operated and unoperated adults with Marfan syndrome." | 9.17 | Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. ( de Waard, V; den Hartog, AW; Franken, R; Groenink, M; Marquering, HA; Mulder, BJ; Radonic, T; Scholte, AJ; Spijkerboer, AM; Timmermans, J; van den Berg, MP; Zwinderman, AH, 2013) |
| "To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS)." | 9.17 | Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. ( Chen, CA; Chiu, HH; Chiu, SN; Hu, FC; Lin, MT; Lu, CW; Wang, JK; Wu, MH, 2013) |
| "A case of severe early-onset Marfan syndrome (MFS) led us to ask the question: 'Should an ARB, particularly losartan [intervention], compared with beta blockade alone [comparison], be commenced in all paediatric MFS patients [patient] with aortic root dilatation [outcome]?' The current literature was critically appraised to address this question." | 7.81 | Losartan therapy for cardiac disease in paediatricMarfan syndrome. ( Adès, L; Ewans, LJ; Roberts, P, 2015) |
| "Despite the retrospective design of the study and the small sample size, a beneficial effect of losartan therapy was observed in pediatric patients with Marfan syndrome in the mid and long term." | 7.81 | [Aortic root dilatation rate in pediatric patients with Marfan syndrome treated with losartan]. ( Angeli, E; Bonvicini, M; Donti, A; Gargiulo, GD; Guidarini, M; Lovato, L; Mariucci, E; Picchio, FM; Wischmeijer, A, 2015) |
| "Long-term outcome of Marfan syndrome patients randomly assigned to losartan or atenolol showed no differences in aortic dilation rate or presence of clinical events between treatment groups." | 5.27 | Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. ( Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G, 2018) |
| "To evaluate the benefit of adding Losartan to baseline therapy in patients with Marfan syndrome (MFS)." | 5.20 | Marfan Sartan: a randomized, double-blind, placebo-controlled trial. ( Aegerter, P; Arnoult, F; Attias, D; Barthelet, M; Basquin, A; Boileau, C; Collignon, P; Delorme, G; Detaint, D; Dulac, Y; Dupuis-Girod, S; Edouard, T; Faivre, L; Habib, G; Jondeau, G; Milleron, O; Naudion, S; Odent, S; Pangaud, N; Plauchu, H; Ropers, J; Sassolas, F; Thomas-Chabaneix, J; Tubach, F; Wolf, JE, 2015) |
| "In this multicentre, open-label, randomized controlled trial with blinded assessments, we compared losartan treatment with no additional treatment in operated and unoperated adults with Marfan syndrome." | 5.17 | Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. ( de Waard, V; den Hartog, AW; Franken, R; Groenink, M; Marquering, HA; Mulder, BJ; Radonic, T; Scholte, AJ; Spijkerboer, AM; Timmermans, J; van den Berg, MP; Zwinderman, AH, 2013) |
| "To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS)." | 5.17 | Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. ( Chen, CA; Chiu, HH; Chiu, SN; Hu, FC; Lin, MT; Lu, CW; Wang, JK; Wu, MH, 2013) |
| "This study confirms that angiotensin II type 1 receptor antagonism (losartan) decreases aortic aneurysm growth in a mouse model of MFS." | 3.88 | The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome. ( Clijsters, M; Herijgers, P; Meuris, B; Schepens, J; Verbrugghe, P; Verhoeven, J; Vervoort, D, 2018) |
| "A case of severe early-onset Marfan syndrome (MFS) led us to ask the question: 'Should an ARB, particularly losartan [intervention], compared with beta blockade alone [comparison], be commenced in all paediatric MFS patients [patient] with aortic root dilatation [outcome]?' The current literature was critically appraised to address this question." | 3.81 | Losartan therapy for cardiac disease in paediatricMarfan syndrome. ( Adès, L; Ewans, LJ; Roberts, P, 2015) |
| "Despite the retrospective design of the study and the small sample size, a beneficial effect of losartan therapy was observed in pediatric patients with Marfan syndrome in the mid and long term." | 3.81 | [Aortic root dilatation rate in pediatric patients with Marfan syndrome treated with losartan]. ( Angeli, E; Bonvicini, M; Donti, A; Gargiulo, GD; Guidarini, M; Lovato, L; Mariucci, E; Picchio, FM; Wischmeijer, A, 2015) |
| " Currently, the most promising therapeutic drug in Marfan syndrome is losartan, by blocking the angiotensin II receptor type 1 and thereby inhibiting pSmad2 signaling." | 3.80 | No beneficial effect of general and specific anti-inflammatory therapies on aortic dilatation in Marfan mice. ( de Vries, CJ; de Waard, V; den Hartog, AW; Franken, R; Groenink, M; Hibender, S; Mulder, BJ; Radonic, T; Zwinderman, AH, 2014) |
| "Statins are similar to losartan in attenuating aortic root dilation in a mouse model of Marfan syndrome." | 3.77 | Pravastatin reduces Marfan aortic dilation. ( Black, A; Byrne, J; Dietz, HC; Hill, AD; Huuskonen, V; Kay, E; Kearney, S; McAllister, H; McGuinness, J; McLoughlin, D; Redmond, JM; Terzo, E, 2011) |
| "Treatment with losartan significantly blocked TAC-induced vascular inflammation and macrophage accumulation." | 1.39 | Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade. ( Brasier, AR; Cao, JM; Geng, L; Guo, S; Kuang, SQ; Kwartler, CS; Milewicz, DM; Peters, AM; Prakash, SK; Villamizar, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Sawada, H | 1 |
| Ohno-Urabe, S | 1 |
| Ye, D | 1 |
| Franklin, MK | 1 |
| Moorleghen, JJ | 1 |
| Howatt, DA | 1 |
| Mullick, AE | 1 |
| Daugherty, A | 1 |
| Lu, HS | 1 |
| Woudstra, OI | 1 |
| Ghanam, A | 1 |
| Vliegen, HW | 1 |
| van Dijk, APJ | 1 |
| van Melle, JP | 1 |
| Groenink, M | 4 |
| Meijboom, FJ | 1 |
| Post, MC | 1 |
| Mulder, BJM | 1 |
| Bouma, BJ | 1 |
| Bokma, JP | 1 |
| Flyer, JN | 1 |
| Sleeper, LA | 1 |
| Colan, SD | 1 |
| Singh, MN | 1 |
| Lacro, RV | 1 |
| Verbrugghe, P | 1 |
| Verhoeven, J | 1 |
| Clijsters, M | 1 |
| Vervoort, D | 1 |
| Schepens, J | 1 |
| Meuris, B | 1 |
| Herijgers, P | 1 |
| Teixido-Tura, G | 1 |
| Forteza, A | 1 |
| Rodríguez-Palomares, J | 1 |
| González Mirelis, J | 1 |
| Gutiérrez, L | 1 |
| Sánchez, V | 1 |
| Ibáñez, B | 1 |
| García-Dorado, D | 1 |
| Evangelista, A | 1 |
| Kang, YN | 1 |
| Chi, SC | 1 |
| Wu, MH | 2 |
| Chiu, HH | 2 |
| Kuang, SQ | 1 |
| Geng, L | 1 |
| Prakash, SK | 1 |
| Cao, JM | 1 |
| Guo, S | 1 |
| Villamizar, C | 1 |
| Kwartler, CS | 1 |
| Peters, AM | 1 |
| Brasier, AR | 1 |
| Milewicz, DM | 1 |
| Elshershari, H | 1 |
| Harris, C | 1 |
| den Hartog, AW | 2 |
| Franken, R | 3 |
| Radonic, T | 2 |
| de Waard, V | 3 |
| Timmermans, J | 2 |
| Scholte, AJ | 2 |
| van den Berg, MP | 2 |
| Spijkerboer, AM | 1 |
| Marquering, HA | 1 |
| Zwinderman, AH | 3 |
| Mulder, BJ | 3 |
| Hibender, S | 1 |
| de Vries, CJ | 1 |
| Milleron, O | 1 |
| Arnoult, F | 1 |
| Ropers, J | 1 |
| Aegerter, P | 1 |
| Detaint, D | 1 |
| Delorme, G | 1 |
| Attias, D | 1 |
| Tubach, F | 1 |
| Dupuis-Girod, S | 1 |
| Plauchu, H | 1 |
| Barthelet, M | 1 |
| Sassolas, F | 1 |
| Pangaud, N | 1 |
| Naudion, S | 1 |
| Thomas-Chabaneix, J | 1 |
| Dulac, Y | 1 |
| Edouard, T | 1 |
| Wolf, JE | 1 |
| Faivre, L | 1 |
| Odent, S | 1 |
| Basquin, A | 1 |
| Habib, G | 1 |
| Collignon, P | 1 |
| Boileau, C | 1 |
| Jondeau, G | 1 |
| El Morabit, A | 1 |
| Marquering, H | 1 |
| Planken, NR | 1 |
| Lüscher, TF | 1 |
| Ewans, LJ | 1 |
| Roberts, P | 1 |
| Adès, L | 1 |
| Mariucci, E | 1 |
| Guidarini, M | 1 |
| Donti, A | 1 |
| Lovato, L | 1 |
| Wischmeijer, A | 1 |
| Angeli, E | 1 |
| Gargiulo, GD | 1 |
| Picchio, FM | 1 |
| Bonvicini, M | 1 |
| Gao, L | 1 |
| Chen, L | 1 |
| Fan, L | 1 |
| Gao, D | 1 |
| Liang, Z | 1 |
| Wang, R | 1 |
| Lu, W | 1 |
| Aquilina, K | 1 |
| Hobbs, C | 1 |
| Tucker, A | 1 |
| Whitelaw, A | 1 |
| Thoresen, M | 1 |
| Gambarin, FI | 1 |
| Favalli, V | 1 |
| Serio, A | 1 |
| Regazzi, M | 1 |
| Pasotti, M | 1 |
| Klersy, C | 1 |
| Dore, R | 1 |
| Mannarino, S | 1 |
| Viganò, M | 1 |
| Odero, A | 1 |
| Amato, S | 1 |
| Tavazzi, L | 1 |
| Arbustini, E | 1 |
| McLoughlin, D | 1 |
| McGuinness, J | 1 |
| Byrne, J | 1 |
| Terzo, E | 1 |
| Huuskonen, V | 1 |
| McAllister, H | 1 |
| Black, A | 1 |
| Kearney, S | 1 |
| Kay, E | 1 |
| Hill, AD | 1 |
| Dietz, HC | 1 |
| Redmond, JM | 1 |
| Wang, JK | 1 |
| Lu, CW | 1 |
| Chiu, SN | 1 |
| Chen, CA | 1 |
| Lin, MT | 1 |
| Hu, FC | 1 |
| Krohn, J | 1 |
| Bjune, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome[NCT00763893] | Phase 3 | 303 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to A similar publication has been released, suggesting a beneficial effect of sartans, and only 15 patients remained to be seen for their visit at 36 months.) | ||
| Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124] | Phase 3 | 291 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR)[NCT02679261] | Phase 3 | 220 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome[NCT00651235] | Phase 2 | 44 participants (Anticipated) | Interventional | 2007-02-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for losartan and Dilatation, Pathologic
| Article | Year |
|---|---|
The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Aortic Diseases; Cardiotonic Agents; | 2020 |
The effect of losartan on progressive aortic dilatation in patients with Marfan's syndrome: a meta-analysis of prospective randomized clinical trials.
Topics: Aortic Diseases; Dilatation, Pathologic; Echocardiography; Female; Humans; Losartan; Magnetic Resona | 2016 |
7 trials available for losartan and Dilatation, Pathologic
| Article | Year |
|---|---|
The aortic root in repaired tetralogy of Fallot: Serial measurements and impact of losartan treatment.
Topics: Adult; Aorta; Aortic Diseases; Dilatation, Pathologic; Female; Humans; Losartan; Male; Middle Aged; | 2021 |
Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aorti | 2018 |
Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Aorta, Thoracic; Aortic Diseases; Dilatation, Pathol | 2013 |
Marfan Sartan: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Aorti | 2015 |
Increased aortic tortuosity indicates a more severe aortic phenotype in adults with Marfan syndrome.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aortic Diseases; Aortic Dissection; Dilatatio | 2015 |
Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Aneu | 2009 |
Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Aortic | 2013 |
12 other studies available for losartan and Dilatation, Pathologic
| Article | Year |
|---|---|
Inhibition of the Renin-Angiotensin System Fails to Suppress β-Aminopropionitrile-Induced Thoracic Aortopathy in Mice-Brief Report.
Topics: Aminopropionitrile; Angiotensin II; Angiotensinogen; Animals; Aortic Aneurysm, Thoracic; Aortic Rupt | 2022 |
Effect of Losartan or Atenolol on Children and Young Adults With Bicuspid Aortic Valve and Dilated Aorta.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; | 2021 |
The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Aneurysm; Dilatation, Pathologic; Di | 2018 |
Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Aortic Aneurysm, T | 2013 |
Paternal fibrillin-1 mutation transmitted to an affected son with neonatal marfan syndrome: the importance of early recognition.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Aorta; Dilatation, Pathologic; | 2014 |
No beneficial effect of general and specific anti-inflammatory therapies on aortic dilatation in Marfan mice.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Dilatation, Pathologic; Losartan; Marfan Syndrome; Mice; M | 2014 |
Atherosclerosis, neoatherosclerosis, and vascular disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Aortic Valve Stenosis; Cardiovascular Dise | 2015 |
Losartan therapy for cardiac disease in paediatricMarfan syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Aorta; Dilatation, Pathologic; Female; Heart Defects, Conge | 2015 |
[Aortic root dilatation rate in pediatric patients with Marfan syndrome treated with losartan].
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Aortic Valve; Bicuspid Aortic Valve Disease; Ch | 2015 |
Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-St | 2008 |
Pravastatin reduces Marfan aortic dilation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Dilatation, Pathologic; Di | 2011 |
Uveal effusion and angle-closure glaucoma in primary pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Conjunctiva; Corneal Edema; Dilatation, Pathologic; Female; Glaucoma, | 2003 |